View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
March 24, 2022updated 28 Mar 2022 5:53am

Mycobacterium Infections accounts for 1.9% share of global Infectious Disease clinical trial activity in 2021

By Carmen

Mycobacterium Infections accounted for a 1.9% share of the global clinical trials within the Infectious Disease therapy area in 2021, registering a decrease of 1.9% when compared with the last ten-year average of 3.8% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Mycobacterium Infections

Industry sponsored trials held a 29.8% share of all the clinical trials for Mycobacterium Infections indication in 2021, registering a decrease of 2.6% when compared with the ten-year average of 32.4%. Non-industry sponsored trials accounted for a 70.2% share in 2021, registering an increase of 2.6% over the ten-year average of 67.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Mycobacterium Infections trials

Asia-Pacific was the top region for industry sponsored Mycobacterium Infections trials, accounting for a 56.7% share in 2021, when compared with the five-year average of 65.1% and ten-year average of 52.1%.

Europe was at the second position with a 30.0% share in 2021, over the five-year average of 30.9% and ten-year average of 38.8%, followed by Middle East and Africa with a 10.0% share in 2021, as against five-year and ten-year averages of 18.7% and 20.9% respectively.

North America stood fourth with a 3.3% share in 2021, compared with the five-year average of 7.2% and ten-year average of 9.2%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 8.4% and 7.6% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Mycobacterium Infections trials, accounting for a 30.0% share in 2021, as against the five-year average of 38.7% and ten-year average of 24.5%.

Russia held a 30.0% share in 2021, over the five-year average of 16.3% and ten-year average of 24.7%, followed by Japan with a 10.0% share in 2021, compared with the five-year and ten-year averages of 4.4% and 3.4% respectively.

South Korea held a 6.7% share in 2021, as against the five-year average of 9.3% and ten-year average of 6.5%.

Iran held a 6.7% share in 2021, over the five-year and ten-year averages of 0.0% and 0.0% respectively.

Top regions of non-industry sponsored Mycobacterium Infections trials

Asia-Pacific was the top region for non-industry sponsored Mycobacterium Infections trials, accounting for a 44.9% share in 2021 when compared with the five-year average of 57.8% and ten-year average of 49.4%.

Middle East and Africa was at the second position with a 39.1% share in 2021, over the five-year and ten-year averages of 26.6% and 31.5% respectively, followed by Europe with a 15.9% share in 2021, as against the five-year average of 16.0% and ten-year average of 18.1%.

North America stood at the fourth position with a 13.0% share in 2021, compared with the five-year average of 11.6% and ten-year average of 10.4%, followed by South and Central America with a 5.8% share in 2021, over the five-year and ten-year averages of 6.9% and 6.1% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

South Africa was the top country for non-industry sponsored Mycobacterium Infections trials, accounting for a 21.7% share in 2021, as against the five-year average of 16.1% and ten-year average of 18.5%.

China held a 17.4% share in 2021, over the five-year average of 24.5% and ten-year average of 18.4%, followed by India with a 15.9% share, compared with the five-year and ten-year averages of 12.5% and 10.5% respectively.

The US held a 13.0% share in 2021, as against the five-year average of 8.7% and ten-year average of 8.2%.

Uganda held a 7.2% share in 2021, over the five-year average of 7.0% and ten-year average of 6.3%.

Phase I trials lead industry sponsored clinical trials for Mycobacterium Infections in 2021

Phase I trials held a 64.5% share of industry sponsored clinical trials for Mycobacterium Infections in 2021, over the five-year average of 63.6% and ten-year average of 55.1%.

Phase II trials held a 22.6% share in 2021, as against the five-year average of 15.1% and ten-year average of 18.1%. Phase III trials held a 9.7% share in 2021, compared with the five-year and ten-year averages of 14.7% and 16.7% respectively.

Phase IV trials held a 3.2% share in 2021, over the five-year average of 6.6% and ten-year average of 10.1%.

Phase II trials lead non-industry sponsored clinical trials for Mycobacterium Infections in 2021

Phase II trials held a 34.2% share of non-industry sponsored clinical trials for Mycobacterium Infections in 2021, over the five-year average of 44.6% and ten-year average of 42.9%.

Phase IV trials held a 30.1% share in 2021, as against the five-year average of 18.9% and ten-year average of 19.4%. Phase III trials held a 23.3% share, compared with the five-year and ten-year averages of 20.7% and 19.4% respectively.

Phase I trials held a 12.3% share in 2021, over the five-year average of 15.9% and ten-year average of 18.3%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena